HealthQuill Cancer treatments
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
Nuvectis Pharma, Inc., a US biopharmaceutical firm, has started its experimental trial in humans to treat solid tumors.
Drugs Health Pharma

US-based Nuvectis Pharma starts human trial on solid tumors

HQ Team September 12, 2023: Nuvectis Pharma, Inc., a US biopharmaceutical firm, has started its experimental trial in humans to treat solid tumors..

Read More